Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
Newron launches a private placement of new shares
Milan, Italy - September 25, 2017 - Newron Pharmaceuticals S.p.A. ("Newron" or the "Company", SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces the launch of a private placement of up to 2,000,000 new shares to institutional investors (representing up to 12.6% of the company's current share capital), with the ordinary shares originating from the capital increases approved and empowered by Newron's shareholders' meetings in 2015 and 2016 (the "Transaction"). In line with the granted shareholders' approvals, option rights of the existing shareholders are excluded.
Newron intends to use the net proceeds of the Transaction for general corporate purposes, including the financing of the Company's operations and research programs and for the development of the Company's current and future pipeline products, with a focus on Evenamide. The Company has a focus on developing drugs for orphan indications and products/product candidates that need specialized regulatory and development efforts. Newron is seeking opportunistic additions to the Company's pipeline portfolio and, if such aforementioned development programs are successful, will explore the possibility of establishing commercialisation operations for certain selected territories.
The new shares will be placed with institutional investors through an accelerated book-building process, which will open with immediate effect. Newron will announce the results of the issuance as soon as possible after the closing of the book-build in a subsequent press release.
In relation to the Transaction, the Company has agreed to a lock-up undertaking for a period of 90 calendar days on future share issuances, subject to certain customary exceptions. The Company's senior management and all members of the Board of Directors have also agreed to a lock-up undertaking for a period of 90 calendar days on future share disposals, subject to customary exceptions. No other parties have entered into any lock-up undertakings.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®(safinamide) has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland and the USA, and is commercialized by Newron's Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson's disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com
For more information, please contact
Media inquiries | Investor and Analyst inquiries |
Newron | Newron |
UK/Europe | UK/Europe |
Switzerland | Switzerland |
Germany/Europe | Germany/Europe |
USA | USA |
Provider | Channel | Contact | ||
---|---|---|---|---|
Tensid EQS Ltd., Switzerland www.tensid.ch |
newsbox.ch www.newsbox.ch |
Provider/Channel related enquiries marco@tensid.ch +41 41 763 00 50 |